Research programme: anticancer therapeutics - Jerini/MerckAlternative Names: PIN 1 inhibitors - Jerini/Merck
Latest Information Update: 04 Dec 2007
At a glance
- Originator Jerini
- Developer Jerini; Merck KGaA
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jul 2006 No development reported - Preclinical for Cancer in Germany (unspecified route)
- 04 Feb 2004 Preclinical trials in Cancer in Germany (unspecified route)